These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 34214403)

  • 1. Alternative use of buprenorphine among people who use opioids in three U.S. Cities.
    Gandhi P; Rouhani S; Park JN; Urquhart GJ; Allen ST; Morales KB; Green TC; Sherman SG
    Subst Abus; 2022; 43(1):364-370. PubMed ID: 34214403
    [No Abstract]   [Full Text] [Related]  

  • 2. Harm reduction measures employed by people using opioids with suspected fentanyl exposure in Boston, Baltimore, and Providence.
    Rouhani S; Park JN; Morales KB; Green TC; Sherman SG
    Harm Reduct J; 2019 Jun; 16(1):39. PubMed ID: 31234942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of willingness to enroll in opioid agonist treatment among opioid dependent people who inject drugs in Ukraine.
    Makarenko I; Mazhnaya A; Polonsky M; Marcus R; Bojko MJ; Filippovych S; Springer S; Dvoriak S; Altice FL
    Drug Alcohol Depend; 2016 Aug; 165():213-20. PubMed ID: 27370527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preference for drugs containing fentanyl from a cross-sectional survey of people who use illicit opioids in three United States cities.
    Morales KB; Park JN; Glick JL; Rouhani S; Green TC; Sherman SG
    Drug Alcohol Depend; 2019 Nov; 204():107547. PubMed ID: 31536877
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient, prescriber, and Community factors associated with filled naloxone prescriptions among patients receiving buprenorphine 2017-18.
    Stein BD; Jones CM; Smart R; Sheng F; Sorbero M
    Drug Alcohol Depend; 2021 Apr; 221():108569. PubMed ID: 33578296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methamphetamine use and utilization of medications for opioid use disorder among rural people who use drugs.
    Tsui JI; Whitney BM; Korthuis PT; Chan B; Pho MT; Jenkins WD; Young AM; Cooper HLF; Friedmann PD; Stopka TJ; de Gijsel D; Miller WC; Go VF; Westergaard R; Brown R; Seal DW; Zule WA; Feinberg J; Smith GS; Mixson LS; Fredericksen R; Crane HM; Delaney JA;
    Drug Alcohol Depend; 2023 Sep; 250():110911. PubMed ID: 37549545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence.
    Sherman SG; Morales KB; Park JN; McKenzie M; Marshall BDL; Green TC
    Int J Drug Policy; 2019 Jun; 68():46-53. PubMed ID: 30991301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlates of concurrent use of stimulants and opioids among people who access harm reduction services in British Columbia, Canada: Findings from the 2019 Harm Reduction Client Survey.
    Lukac CD; Steinberg A; Papamihali K; Mehta A; Lock K; Buxton JA
    Int J Drug Policy; 2022 Apr; 102():103602. PubMed ID: 35124412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Associations between prescribed benzodiazepines, overdose death and buprenorphine discontinuation among people receiving buprenorphine.
    Park TW; Larochelle MR; Saitz R; Wang N; Bernson D; Walley AY
    Addiction; 2020 May; 115(5):924-932. PubMed ID: 31916306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sociodemographic and prescribing characteristics that impact long-term retention in buprenorphine treatment for opioid use disorder among a statewide population.
    Hallowell BD; Chambers LC; Samuels EA; Bratberg J; McDonald J; Nitenson A; Onyejekwe C; Beaudoin FL
    Drug Alcohol Depend; 2022 Dec; 241():109680. PubMed ID: 36335834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Patients' Direct Addition of Buprenorphine to Urine Drug Test Specimens With Clinical Factors in Opioid Use Disorder.
    Pytell JD; Whitley P; Passik SD; Bundy WL; Dawson E; Saloner B
    JAMA Psychiatry; 2023 May; 80(5):459-467. PubMed ID: 36947029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examining buprenorphine diversion through a harm reduction lens: an agent-based modeling study.
    Adams JW; Duprey M; Khan S; Cance J; Rice DP; Bobashev G
    Harm Reduct J; 2023 Oct; 20(1):150. PubMed ID: 37848945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opioid withdrawal symptoms, frequency, and pain characteristics as correlates of health risk among people who inject drugs.
    Bluthenthal RN; Simpson K; Ceasar RC; Zhao J; Wenger L; Kral AH
    Drug Alcohol Depend; 2020 Jun; 211():107932. PubMed ID: 32199668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying pathways to recent non-fatal overdose among people who use opioids non-medically: How do psychological pain and unmet mental health need contribute to overdose risk?
    Tomko C; Schneider KE; Rouhani S; Urquhart GJ; Nyeong Park J; Morris M; Sherman SG
    Addict Behav; 2022 Apr; 127():107215. PubMed ID: 34953432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trends in opioid initiation among people who use opioids in three US cities.
    Rouhani S; Park JN; Morales KB; Green TC; Sherman SG
    Drug Alcohol Rev; 2020 May; 39(4):375-383. PubMed ID: 32249463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A predictive risk model for nonfatal opioid overdose in a statewide population of buprenorphine patients.
    Chang HY; Krawczyk N; Schneider KE; Ferris L; Eisenberg M; Richards TM; Lyons BC; Jackson K; Weiner JP; Saloner B
    Drug Alcohol Depend; 2019 Aug; 201():127-133. PubMed ID: 31207453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
    Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
    JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between treatment setting and outcomes among oregon medicaid patients with opioid use disorder: a retrospective cohort study.
    Hartung DM; Markwardt S; Johnston K; Geddes J; Baker R; Leichtling G; Hildebran C; Chan B; Cook RR; McCarty D; Ghitza U; Korthuis PT
    Addict Sci Clin Pract; 2022 Aug; 17(1):45. PubMed ID: 35986384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
    Geddes L; Iversen J; Wand H; Maher L
    Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.